Christelle Huguet

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Part of Ipsen SA, Ipsen Innovation SASU is a French biopharmaceutical company that focuses on improving patients' lives through research and innovation in oncology, rare disease, and neuroscience. Ipsen Innovation is based in Les Ulis, France. The private company aims to prolong patients' lives, improve health outcomes, and create a positive impact for patients and society. The company was founded in 1996, and the CEOs are Christelle Huguet and Jose Camara Ferrer.